// App-Quantinova.ai

5073 : Post-treatment alterations in 18F-dihydrotestosterone (FDHT) and FDG PET/CT in metastatic castration-resistant prostate cancer (mCRPC) treated with cabozantinib.

Researchers

Presenter

  • Josef J. Fox

Principal Investigators

  • Eric C. Haupt

  • John Humm

  • Karen A. Autio

  • Dana E. Rathkopf

  • Hebert Alberto Vargas

  • Heiko Schoeder

  • Hedvig Hricak

  • Steven M. Larson

  • Howard I. Scher

  • Michael J. Morris

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • 18F-fluorodeoxyglucose

  • Prostate specific antigen

Drug/Treatment

  • Dihydrotestosterone

  • Cabozantinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00588185

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved